High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.

about

High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.

Item

http://www.wikidata.org/entity/Q49852158

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@en

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@nl

type

Item

label

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@en

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@nl

prefLabel

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@en

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@nl

P1476

High expression of endoglin in ...... e to neoadjuvant chemotherapy.

@en

P2093

Chien-Ting Liu

http://www.w3.org/2001/XMLSchema#string

Fong-Fu Chou

http://www.w3.org/2001/XMLSchema#string

Kun-Ming Rau

http://www.w3.org/2001/XMLSchema#string

Meng-Che Hsieh

http://www.w3.org/2001/XMLSchema#string

Shan-Hsuan Li

http://www.w3.org/2001/XMLSchema#string

Shis-Chung Wu

http://www.w3.org/2001/XMLSchema#string

Tai-Jan Chiu

http://www.w3.org/2001/XMLSchema#string

Yen-Hao Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes

Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Global cancer statistics, 2012

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

P304

7185-7190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2017.7555

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yu-Li Su

P577

2017-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28944897

http://www.w3.org/2001/XMLSchema#string

P932

5865844

http://www.w3.org/2001/XMLSchema#string